Page last updated: 2024-08-26

deoxypyridinoline and Parkinson Disease

deoxypyridinoline has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Honda, Y; Iwamoto, J; Sato, Y	1

Trials

1 trial(s) available for deoxypyridinoline and Parkinson Disease

Article	Year
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology, 2007, Mar-20, Volume: 68, Issue:12 Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Ergocalciferols; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Parkinson Disease; Placebo Effect; Prospective Studies; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome; Vitamin D Deficiency	2007

Article

Year

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.

Neurology, 2007, Mar-20, Volume: 68, Issue:12

Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Ergocalciferols; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Parkinson Disease; Placebo Effect; Prospective Studies; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome; Vitamin D Deficiency

2007